Literature DB >> 444789

Clinical response and tricyclic plasma levels during treatment with clomipramine.

L Della Corte, A D Broadhurst, G P Sgaragli, S Filippini, A F Heeley, H D James, C Faravelli, A Pazzagli.   

Abstract

Fifty depressed in-patients at two psychiatric units, one in Italy the other in England, were treated with clomipramine, either orally, or intravenously and orally. A comparison of clinical response with plasma levels of clomipramine and its metabolite, desmethylclomipramine, showed clear relationships especially in the case of desmethylclomipramine. In the intravenously-treated group this was linear, in the orally-treated group it was curvilinear. Plasma levels of desmethylclomipramine and administered clomipramine correlate highly. These findings, together with the fact that significant clinical improvement was observed in only 55% of the patients, suggest that titration of the administered dose to obtain more effective plasma levels of the metabolite might improve the clinical response to the drug in some patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 444789     DOI: 10.1192/bjp.134.4.390

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  10 in total

1.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

3.  Central and peripheral 5-HT uptake in rats treated chronically with femoxetine, paroxetine, and chlorimipramine.

Authors:  J B Lassen; J Lund; I Søndergaard
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

Review 4.  Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.

Authors:  D McTavish; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of clomipramine.

Authors:  A E Balant-Gorgia; M Gex-Fabry; L P Balant
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 6.  Current antidepressant drugs: their clinical use.

Authors:  L E Hollister
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

7.  Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.

Authors:  B Vandel; S Vandel; J M Jounet; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux.

Authors:  Mario Rossi; Eliana Rosa Munarriz; Stefano Bartesaghi; Marco Milanese; David Dinsdale; Maria Azucena Guerra-Martin; Edward T W Bampton; Paul Glynn; Giambattista Bonanno; Richard A Knight; Pierluigi Nicotera; Gerry Melino
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285

9.  Plasma and brain pharmacokinetics of amitriptyline and its demethylated and hydroxylated metabolites after acute intraperitoneal injection in mice.

Authors:  F Coudore; J Fialip; A Eschalier; J Lavarenne
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jan-Mar       Impact factor: 2.441

10.  Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group.

Authors: 
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.